CL2024002389A1 - Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética - Google Patents

Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética

Info

Publication number
CL2024002389A1
CL2024002389A1 CL2024002389A CL2024002389A CL2024002389A1 CL 2024002389 A1 CL2024002389 A1 CL 2024002389A1 CL 2024002389 A CL2024002389 A CL 2024002389A CL 2024002389 A CL2024002389 A CL 2024002389A CL 2024002389 A1 CL2024002389 A1 CL 2024002389A1
Authority
CL
Chile
Prior art keywords
melanocortin
treat
prevent
receptor agonist
genetic disease
Prior art date
Application number
CL2024002389A
Other languages
English (en)
Spanish (es)
Inventor
Dong Park Hee
Kyeong Hwang Hye
Jin Yeo Su
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CL2024002389A1 publication Critical patent/CL2024002389A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2024002389A 2022-02-08 2024-08-08 Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética CL2024002389A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20220016377 2022-02-08

Publications (1)

Publication Number Publication Date
CL2024002389A1 true CL2024002389A1 (es) 2025-01-31

Family

ID=87564659

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002389A CL2024002389A1 (es) 2022-02-08 2024-08-08 Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética

Country Status (13)

Country Link
US (1) US20250134898A1 (cg-RX-API-DMAC7.html)
EP (1) EP4461297A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505229A (cg-RX-API-DMAC7.html)
KR (1) KR20230120106A (cg-RX-API-DMAC7.html)
CN (1) CN119300835A (cg-RX-API-DMAC7.html)
AR (1) AR128463A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023218785A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248118A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002389A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024011882A2 (cg-RX-API-DMAC7.html)
MX (1) MX2024009854A (cg-RX-API-DMAC7.html)
TW (1) TWI838114B (cg-RX-API-DMAC7.html)
WO (1) WO2023153762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3202315A1 (en) * 2020-12-22 2022-06-30 Hee Dong Park Use as selective agonist of malanocortin-4 receptor
KR20250046623A (ko) * 2023-09-27 2025-04-03 주식회사 엘지화학 멜라노코르틴-4 수용체 효능제의 pcsk1 결핍 적응증과 연관된 희귀성 유전적 비만질환의 예방 또는 치료 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
US12516047B2 (en) * 2019-11-07 2026-01-06 Lg Chem, Ltd. Melanocortin-4 receptor agonists
CN116507615A (zh) * 2020-10-29 2023-07-28 株式会社Lg化学 黑皮质素受体激动剂化合物的晶型i及其制备方法
TWI804170B (zh) * 2021-01-21 2023-06-01 南韓商Lg化學股份有限公司 黑皮質素-4受體促效劑的用途
TWI826938B (zh) * 2021-02-26 2023-12-21 南韓商Lg化學股份有限公司 黑皮質素-4受體促效劑
TWI861780B (zh) * 2022-03-28 2024-11-11 南韓商Lg化學股份有限公司 預防或治療肥胖的聯合療法

Also Published As

Publication number Publication date
JP2025505229A (ja) 2025-02-21
AU2023218785A1 (en) 2024-08-22
CA3248118A1 (en) 2025-01-24
WO2023153762A1 (ko) 2023-08-17
EP4461297A4 (en) 2025-04-09
TW202339761A (zh) 2023-10-16
CN119300835A (zh) 2025-01-10
AR128463A1 (es) 2024-05-08
CO2024011882A2 (es) 2025-01-23
TWI838114B (zh) 2024-04-01
EP4461297A1 (en) 2024-11-13
US20250134898A1 (en) 2025-05-01
KR20230120106A (ko) 2023-08-16
MX2024009854A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
CO2024011882A2 (es) Uso del agonista del receptor de melanocortina 4 para prevenir o tratar una enfermedad genética rara de la obesidad
ECSP22092977A (es) Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita
MX2021005011A (es) Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
JOP20220056A1 (ar) مركبات rip1 تثبيطية وطرق عملها واستخدامها
MX388748B (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
MX2023008098A (es) Uso de agonista del receptor de melanocortina-4.
ECSP099371A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
MXPA04002537A (es) Alquinos como inhibidores de metaloproteinasa de matriz.
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
SV2007002146A (es) Difenilimidazopirimidina e imidazol aminas como inhibidores de beta-secretasa ref. am101727
AR109590A2 (es) Régimen posológico para inhibidores de comt
AU2025283528A1 (en) Methods of treating WHSC1-overexpressing cancers by inhibiting SETD2
ECSP10010034A (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
GT200500158A (es) Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa
ECSP055525A (es) Inhibidores de cinasas de tirosina
PA8601001A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
CU20080027A7 (es) Bencimidazoles sustituidos como inhibidores de cinasa
CL2008001238A1 (es) Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un pi
CY1108292T1 (el) Αντικαρκινικο σκευασμα που περιεχει dmxaa
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
CO2024000221A2 (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
PY1978496A (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
DE602006010834D1 (de) Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
MX2024008450A (es) Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones